News

Newborns managed with a new care approach for opioid withdrawal were more likely than those receiving traditional care to breastfeed. The findings provide evidence that the care approach may help increase breastfeeding among infants experiencing opioid withdrawal.

NICHD is co-hosting several workshops and virtual meetings on women’s health topics in summer 2024. Please consider registering to participate in discussions and to help shape future research and care.

An NIH-funded study suggests that fenoprofen may be a potential therapeutic for endometriosis, a disease that affects approximately 1 in 10 U.S. women. The researchers used a computer algorithm to evaluate nearly 1,300 existing drugs and tested their top candidate, fenoprofen, in a rodent model of the disease.

NICHD’s Tracey Rouault, M.D., has had many notable achievements during her nearly four-decade career in the intramural program at NIH. Learn about her upbringing, career path, and accomplishments.

The experimental drug TEMPOL prevents viral replication by targeting the SARS-CoV-2 helicase, in addition to the virus’ replicase, according to a new NICHD study.

Read about NICHD’s research findings and activities from 2022.

The experimental drug TEMPOL prevents viral replication and reduces disease severity in a hamster model of COVID-19, according to a new study led by NICHD.

Drug labels for diazepam and clindamycin now include better information for healthcare providers on recommended usage and dosage in pediatric populations.

The Division of Intramural Research provides fundamental knowledge about the nature and behavior of living systems through basic, clinical, and population-based research.

The Division of Intramural Research provides fundamental knowledge about the nature and behavior of living systems through basic, clinical, and population-based research.

The Division of Intramural Research provides fundamental knowledge about the nature and behavior of living systems through basic, clinical, and population-based research.

Read about NICHD’s research findings and activities from 2021.

Dr. Bianchi discusses NICHD-led research on long COVID in children.

NIH-funded study explains how intravenous immune globulin helps children with rare COVID condition.

The experimental drug TEMPOL may be a promising oral antiviral treatment for COVID-19, suggests a study by researchers at NIH.

Looking back and looking ahead. NICHD Director Dr. Diana W. Bianchi joins other leaders across NIH in reflecting on the work of the Rapid Acceleration of Diagnostics (RADx) program and discussing plans for the future.

For many COVID-19 patients, full recovery remains elusive even long after they should feel “better.” NIH recently announced research opportunities to understand COVID-19 long haulers, who have what researchers now refer to as Post-acute sequelae of SARS-CoV-2 infection (PASC). NICHD joins these opportunities while remaining focused on PASC patients within our audiences of interest—pregnant and lactating people, children, and those with disabilities.

Read about NICHD’s research findings and activities from 2020.

The pandemic reinforces why the NIH INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project matters to families and communities.

NIH has launched a new initiative that will combat the growing problem of maternal mortality and morbidity in the United States.